Zhejiang medicine price negotiation varieties come out! Not included in the proportion of drugs, "hepatitis C God drug" suofebuwei was selected, Hengrui, Novartis, Bayer and other enterprises 7 products were not selected!

Source: e drug manager 2017-12-27 Zhejiang serious illness insurance special drug negotiation results came out, 28 varieties were selected, 7 varieties were not selected, the selected products will not be included in the proportion of drugs On December 25, the official website of the Department of human resources and social security of Zhejiang Province released the announcement on the negotiation results of special drugs for serious illness insurance in Zhejiang Province This time, 28 varieties from Pfizer, Merck, Zhengda Tianqing, Haizheng Pfizer and other enterprises were selected, and 7 varieties were not selected As for the negotiation, Zhejiang Provincial Department of human resources and social security said that according to the requirements of "three breakthroughs" in the province's health insurance reform, the burden of patients with serious diseases should be further reduced After being recommended by the health and family planning department and some authoritative medical institutions, Zhejiang provincial consultation expert group on special drugs for serious diseases insurance demonstrated and reported to the leading group of "three breakthroughs" in the health insurance reform of Zhejiang Province for approval, relevant experts should be organized from December 22 to 24 Negotiation on special drugs for serious illness insurance As for the price change and decrease of negotiated varieties, the personnel of Zhejiang Provincial Department of human resources and social security told e pharmaceutical manager that after the publicity (January 3, 2018), the price reduction of negotiated varieties would be announced to the society The enterprise personnel involved in the negotiation told e-drug managers that there was no small drop in the negotiation, but the overall feeling of Zhejiang's negotiation was more scientific Who is the loser? On December 14, the Department of human resources and social security of Zhejiang Province issued the announcement on inviting to participate in the negotiation of special drugs for serious illness insurance in Zhejiang Province According to the products announced at that time, there are 35 drugs in total Of these 35 varieties, 8 are renewal negotiation drugs, and the remaining 27 are new negotiation drugs After negotiation, 28 products have been selected, among which sunlong of Novartis, aiyang of Hengrui, tianenfu of Shanghai Weike, giterry of Bi, Shangjie of Pfizer, weijianle + yichery of Alberta, baiwango of Bayer and ramodulin of United therapeutics corporation are the losers It is worth noting that in this Zhejiang drug price negotiation, there are many products that have not been on the market for a long time Suofebuwei (commodity name suofeidi) was on the market in November this year, while Yike of Xi'an YANGSEN was officially on the market for one month in China, and Theresa of AstraZeneca was only approved to be on the market in March this year In addition, Merck's aibitu and Xi'an Janssen's lik, who were not elected in the national drug price negotiation, were included in the serious illness insurance through the negotiation Zhejiang has always been a province with a large medical market Being able to obtain the support of medical insurance for serious diseases means that it is able to expand rapidly in this province According to the notice on further improving the serious illness insurance system issued by Zhejiang on November 21, the compliance medical expenses above the starting payment standard of the serious illness insurance shall be shared by the serious illness insurance fund and individuals, and the minimum payment proportion of the compliance medical expenses of the serious illness insurance shall not be less than 60% in principle What's more, in order to increase the chips in the negotiation of serious illness insurance, Zhejiang requires the health department not to include the proportion of drugs in medical institutions, even if it is included in the purchase of special drugs for serious illness insurance This is the second negotiation on special medication for serious illness insurance in Zhejiang Province For the first time, 15 varieties were selected It is understood that by the end of 2016, there were 285000 patients with serious illness in Zhejiang Province, with a total reimbursement amount of 1.58 billion yuan How to talk about it? For the negotiation process and price reduction, manager e interviewed some enterprises participating in the negotiation, and the other side said that the negotiation was scientific It is understood that there are three rounds of negotiation in total, the first two rounds of quotation and the third round of confirmation The negotiation time of each enterprise is about two hours The whole process of supervision is very strict Zhejiang's negotiation is very rational, and it does not have a clear requirement on how much price reduction is needed It regards price reduction as the main goal Its main baseline is the lowest price in China First of all, the enterprise is honest and trustworthy If the lowest price in China is reported to Zhejiang Province, after the analysis of the negotiation team in Zhejiang Province, the product is indeed clinically necessary and the price is the lowest in China, then the price may not be greatly reduced Of course, the negotiation in Zhejiang Province is not limited to the lowest price in China For some newly listed products, the prices are mainly compared with those in neighboring countries and regions in China If the prices of enterprises in China are relatively high, they will be required to reduce prices substantially It is mainly negotiated through the situation of the province